Novavax Stock Fundamentals
| NVAX Stock | USD 3.89 0.10 2.51% |
Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.
At this time, Novavax's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 15.1 M in 2024, despite the fact that Operating Income is likely to grow to (394.3 M). Novavax | Select Account or Indicator |
Novavax Company Return On Equity Analysis
Novavax's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novavax Return On Equity | -8.98 |
Most of Novavax's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Novavax Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Novavax has a Return On Equity of -8.982. This is 62.53% lower than that of the Biotechnology sector and 75.36% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Novavax Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novavax's current stock value. Our valuation model uses many indicators to compare Novavax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novavax competition to find correlations between indicators driving Novavax's intrinsic value. More Info.Novavax is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . At this time, Novavax's Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Novavax by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novavax's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novavax's earnings, one of the primary drivers of an investment's value.Novavax Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.Novavax is currently under evaluation in return on equity category among related companies.
Novavax Fundamentals
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.55) % | ||||
| Operating Margin | (0.63) % | ||||
| Current Valuation | 288.74 M | ||||
| Shares Outstanding | 139.95 M | ||||
| Shares Owned By Insiders | 4.99 % | ||||
| Shares Owned By Institutions | 57.43 % | ||||
| Number Of Shares Shorted | 43.91 M | ||||
| Price To Earning | (1.36) X | ||||
| Price To Book | 49.52 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 983.71 M | ||||
| Gross Profit | (156.04 M) | ||||
| EBITDA | (373.8 M) | ||||
| Net Income | (545.06 M) | ||||
| Cash And Equivalents | 1.28 B | ||||
| Cash Per Share | 16.31 X | ||||
| Total Debt | 280.63 M | ||||
| Debt To Equity | 8.24 % | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (5.14) X | ||||
| Cash Flow From Operations | (717.56 M) | ||||
| Short Ratio | 5.45 X | ||||
| Earnings Per Share | (5.41) X | ||||
| Target Price | 15.4 | ||||
| Number Of Employees | 1.54 K | ||||
| Beta | 1.6 | ||||
| Market Capitalization | 578.01 M | ||||
| Total Asset | 1.86 B | ||||
| Retained Earnings | (4.82 B) | ||||
| Working Capital | (491.25 M) | ||||
| Current Asset | 287.26 M | ||||
| Current Liabilities | 76.49 M | ||||
| Net Asset | 1.86 B |
About Novavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 241.3 M | 140.2 M | |
| Total Revenue | 983.7 M | 1 B | |
| Cost Of Revenue | 279.5 M | 293.4 M | |
| Stock Based Compensation To Revenue | 0.09 | 0.08 | |
| Sales General And Administrative To Revenue | 0.35 | 0.33 | |
| Research And Ddevelopement To Revenue | 0.67 | 0.63 | |
| Capex To Revenue | (0.06) | (0.06) | |
| Revenue Per Share | 9.76 | 10.25 | |
| Ebit Per Revenue | (0.42) | (0.44) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novavax Piotroski F Score and Novavax Altman Z Score analysis. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.